COVID-19 Infection and Clinical Outcomes in Hospitalized Patients With Rheumatoid Arthritis : Insights From the National Inpatient Sample
© 2024 Greater Baltimore Medical Center..
Background: Coronavirus-19, primarily a respiratory virus, affects multiple organs and can lead to exacerbation of autoimmune or systemic conditions. Patients with autoimmune diseases, rheumatoid arthritis particularly, are susceptible to infection and complications from COVID-19. RA has become well-associated with COVID-19 infections, but large-scale studies evaluating outcomes among this vulnerable group are limited.
Methods: For the retrospective analysis, we used the National Inpatient Sample database to compare COVID-19 patients with and without RA. A total of 1,050,040 adult hospitalizations were included in the study between January 1 to December 31, 2020: COVID-19 with RA (n = 21,545; 2.1%) and COVID-19 without RA (n = 1,028,495; 97.9%). The primary outcome was in-hospital mortality. Secondary outcomes included mechanical ventilation requirement, vasopressor use, cardiac arrest, cardiogenic shock, acute kidney injury, acute kidney injury requiring hemodialysis, gastrostomy, tracheostomy, length of stay, health care utilization costs, and disposition. A secondary analysis evaluating in-hospital mortality and mechanical ventilation with respect to age was conducted.
Results: COVID-19 patients with RA had significantly increased in-hospital mortality compared to COVID-19 patients without RA (12.9% vs 11.1%, adjusted OR [aOR]: 1.2 [95% CI 1.1-1.3], p < 0.001). This cohort also had significantly increased rates of mechanical ventilation, pressor use, and cardiogenic shock.
Conclusions: Given limited large evidence regarding COVID-19 with respect to RA, future research should be focused on this topic to improve outcomes for this subset of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of community hospital internal medicine perspectives - 14(2024), 1 vom: 06., Seite 5-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davis, Monique G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.55729/2000-9666.1288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369717872 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369717872 | ||
| 003 | DE-627 | ||
| 005 | 20240315234239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55729/2000-9666.1288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369717872 | ||
| 035 | |a (NLM)38482087 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Davis, Monique G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Infection and Clinical Outcomes in Hospitalized Patients With Rheumatoid Arthritis |b Insights From the National Inpatient Sample |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Greater Baltimore Medical Center. | ||
| 520 | |a Background: Coronavirus-19, primarily a respiratory virus, affects multiple organs and can lead to exacerbation of autoimmune or systemic conditions. Patients with autoimmune diseases, rheumatoid arthritis particularly, are susceptible to infection and complications from COVID-19. RA has become well-associated with COVID-19 infections, but large-scale studies evaluating outcomes among this vulnerable group are limited | ||
| 520 | |a Methods: For the retrospective analysis, we used the National Inpatient Sample database to compare COVID-19 patients with and without RA. A total of 1,050,040 adult hospitalizations were included in the study between January 1 to December 31, 2020: COVID-19 with RA (n = 21,545; 2.1%) and COVID-19 without RA (n = 1,028,495; 97.9%). The primary outcome was in-hospital mortality. Secondary outcomes included mechanical ventilation requirement, vasopressor use, cardiac arrest, cardiogenic shock, acute kidney injury, acute kidney injury requiring hemodialysis, gastrostomy, tracheostomy, length of stay, health care utilization costs, and disposition. A secondary analysis evaluating in-hospital mortality and mechanical ventilation with respect to age was conducted | ||
| 520 | |a Results: COVID-19 patients with RA had significantly increased in-hospital mortality compared to COVID-19 patients without RA (12.9% vs 11.1%, adjusted OR [aOR]: 1.2 [95% CI 1.1-1.3], p < 0.001). This cohort also had significantly increased rates of mechanical ventilation, pressor use, and cardiogenic shock | ||
| 520 | |a Conclusions: Given limited large evidence regarding COVID-19 with respect to RA, future research should be focused on this topic to improve outcomes for this subset of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Age | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Complications | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a National inpatient sample | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a United States | |
| 700 | 1 | |a Akhlaq, Anum |e verfasserin |4 aut | |
| 700 | 1 | |a Aamer, Sameen |e verfasserin |4 aut | |
| 700 | 1 | |a Shuja, Hina |e verfasserin |4 aut | |
| 700 | 1 | |a Edigin, Ehizogie |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Abu B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of community hospital internal medicine perspectives |d 2011 |g 14(2024), 1 vom: 06., Seite 5-12 |w (DE-627)NLM229425305 |x 2000-9666 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:06 |g pages:5-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55729/2000-9666.1288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 06 |h 5-12 | ||